Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists

J Comp Eff Res. 2020 Jun;9(9):615-625. doi: 10.2217/cer-2020-0001. Epub 2020 May 29.

Abstract

Aim: To analyze the perception of anticoagulation with dabigatran in patients with nonvalvular atrial fibrillation previously treated with vitamin K antagonists over a 6-month period. Materials & methods: This is a prospective, noninterventional, noncontrolled, multicenter study. To assess patients' perceptions, PACT-Q2 questionnaire was completed. Results: Six hundred and fifty nine patients (73.1 ± 9.4 years, CHA2DS2-VASc 3.6 ± 1.6) were included. At baseline, the convenience and satisfaction scores were 60.9 ± 24.9 and 49.9 ± 17.7, respectively. The scores significantly increased along the study. Convenience score was higher in males and in patients with low-moderate thromboembolic risk. Satisfaction score was higher in females. Only 8.0% of patients discontinued dabigatran (3.7% due to side effects). Conclusion: Convenience and satisfaction scores for nonvalvular atrial fibrillation patients treated with dabigatran at 6 months were significantly better than with previous vitamin K antagonists.

Keywords: PACT-Q2 questionnaire; atrial fibrillation; dabigatran; satisfaction; treatment convenience.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Dabigatran / therapeutic use*
  • Female
  • Humans
  • Male
  • Perception
  • Prospective Studies
  • Stroke / prevention & control*
  • Vitamin K / therapeutic use*

Substances

  • Anticoagulants
  • Vitamin K
  • Dabigatran